Industry

– Results from EV-103 trial evaluating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session – BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 … [Read more…]

Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected LA SCCHN Initial results of Phase II INSIGHT 2 study of TEPMETKO plus osimertinib as second-line treatment in EGFR-mutant NSCLC with MET amplification showed encouraging signs … [Read more…]

— 3.2 Month Survival Benefit Demonstrated in Patients who had Already Received Prior Endocrine-based Therapy and at Least Two Prior Chemotherapies — — Trodelvy Now Shows a Survival Benefit in both Pre-treated HR+/HER2- Metastatic Breast Cancer and Second-Line Metastatic Triple-Negative Breast Cancer — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive … [Read more…]

2022 Pittsburgh Heart Walk supporting the American Heart Association sponsored by IDI Consulting PITTSBURGH–(BUSINESS WIRE)–#ITPittsburgh–IDI Consulting is a proud sponsor of the 2022 Pittsburgh Heart Walk happening on September 17th at Point State Park. Join IDI Consulting and other heroes in the community and walk together in the fight against heart disease and stroke. Donations … [Read more…]

Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive … [Read more…]

BOSTON–(BUSINESS WIRE)–Exaktera LLC, (“Exaktera”), a Union Park Capital (“Union Park”) portfolio company, is pleased to announce its acquisition of Advanced Illumination Inc. (“Advanced Illumination”), a long-established design and manufacturer of specialty LED lighting assemblies and drivers for machine vision, industrial imaging, bio-medical and related imaging applications. Terms of the transaction were not disclosed. Advanced Illumination’s … [Read more…]

PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences in September: H.C. Wainwright & Co. Annual Global Investment Conference Tuesday, September 13 at 10:30 a.m. ET Ladenburg Thalmann Healthcare Conference … [Read more…]

Solution offers ready-to-use, provider performance metrics that can be integrated into front-end and back-end healthcare applications to inform both critical business and clinical decisions ARLINGTON, Va.–(BUSINESS WIRE)–CareJourney, the healthcare industry’s leading source of provider cost and quality data, today announced enhancements to its provider performance module on the CareJourney platform. The module can be accessed … [Read more…]

RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it advised Jordi Labs on its sale to RQM+, a portfolio company of Linden Capital Partners (Linden). Jordi Labs provides a full suite of regulatory, investigative and other related analytical chemistry testing services primarily to medical device manufacturers. The transaction was … [Read more…]

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #Affordablemedicines–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U.S. Food and Drug Administration … [Read more…]